Influx Healthtech Limited · NSE:INFLUX
Influx Healthtech — Alpha Ideas SME Conference 2025
34 slides from Influx Healthtech's conference presentation, Aug 22, 2025
Slide 1: Submission of Investor Meet Presentation to Stock Exchange
August 22, 2025 To, Listing Department, National Stock Exchange Limited Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra (E), Mumbai-400 051 Scrip Code – INFLUX Dear Sir/Madam, Sub.: Submission of Investor Meet Presentation to Stock Exchange under Regulation 30 of the SEBI (Listing Obligat
Slide 2: Investor Presentation - August 2025
INVESTOR PRESENTATION - AUGUST 2025
Slide 3: Agenda
Agenda 1. Performance update 2. About Influx Healthtech Limited 3. Competitive moats 4. Investment rationale 5. Historical business performance 6. Select financial statement data 7. Annexures
Slide 4: Performance update and management commentary – FY25
Performance update and management commentary – FY25 ▪ Targeted marketing campaigns and active participation in exhibitions, which enhanced brand visibility and broadened our customer base Business updates ▪ Expanding into pet food production, initially focusing on dog food (kibbles), followed by cat
Slide 5: Revenue split across segments – FY25
Revenue split across segments – FY25 Nutraceuticals (₹ crores) Cosmetics (₹ crores) Ayurvedic (₹ crores) Others1 (₹ crores) 94.0 6.4 1.6 93.5 3.2 1.2 3.0 1.9 FY24 FY25 FY24 FY25 FY24 FY25 FY24 FY25 2% 1% 90% 2% FY24 93% 3% FY25 3% 6% 1 Nutraceuticals Cosmetics Ayurvedic Others 4 1. Others include ve
Slide 6: Agenda
Agenda 1. Performance update 2. 2. About About Influx Influx Healthtech Healthtech Limited Limited 3. Competitive moats 4. Investment rationale 5. Historical business performance 6. Select financial statement data 7. Annexures
Slide 7: Formulation driven, brand focused healthcare company
Formulation driven, brand focused healthcare company About Influx Healthtech Limited Revenue Mix – FY25 (%) Ayurvedic, 3% Veterinary & Homecare, 1% ▪ Founded in 2020 by Dr. Munir Chandniwala, Influx Healthtech is a contract development and manufacturing organization (CDMO) specializing in nutraceuti
Slide 8: Strategic milestones
Strategic milestones Transitioned in a Installed liquid fill Acquired additional private limited capsule technology land in Palghar to company expand into veterinary foods; Kicked-off formulation trials 2003 2021 2023 2025 2020 2021 2024 Entered industry Started Started snacking Became public manufa
Slide 9: Agenda
Agenda 1. Executive summary 2. About Influx Healthtech Limited 3. 3. Competitive Competitive moats moats 4. Investment rationale 5. Historical business performance 6. Select financial statement data 7. Annexures
Slide 10: Sustainable competitive moats
Sustainable competitive moats Well-diversified product portfolio Formulation driven innovation Robust and integrated business model Strong clientele across geographies and industries Capacity expansion for sustained growth Industry leading certification & compliance systems Passionate and purpose-dr
Slide 11: Well-diversified product portfolio
Well-diversified product portfolio Home Care Dietary /Nutritional Supplements Veterinary Feeds 0.1% 1% 90% 105crs. FY25 revenue 3% Ayurvedic /Herbal 6% Cosmetics Our product lines reflect our dedication to bringing cutting edge, science-backed health solutions to consumers Note: Map is not to scale
Slide 12: Actively focused on expanding our product portfolio
Actively focused on expanding our product portfolio 2025 • Pet food for cats 2024 • Nutritional oral gel • Ayurvedic gummies • Oral dissolving powder 2023 • Pet food for dogs • Nutrition toppers for pets 2021 • Popped chips • Nutritional gummies 2022 • Wafer protein bars • Peanut butter bar • Liquid
Slide 13: In-house F&D unit: Key driver in creating innovative, market-ready solutions
In-house F&D unit: Key driver in creating innovative, market-ready solutions ▪ Provide development services including formulation development, process development and analytical development ▪ In-house formulation & development (F&D) team focused on creating new formulations based on current health t
Slide 14: Supporting clients across all stages of development and manufacturing
Supporting clients across all stages of development and manufacturing Contact Influx Sample preparation Label designing Finished Healthtech product New product idea Pricing Finalizing packaging Commercial scale production 13
Slide 15: Strong clientele across geographies and industries
Strong clientele across geographies and industries Number of clients Marquee clients 636 559 538 FY23 FY24 FY25 Develop reliable, palatable formulations that ensure consumer acceptance and long-term client success Work closely with clients to refine formulations for feasibility, cost efficiency, and
Slide 16: Capacity expansion for sustained growth
Capacity expansion for sustained growth Unit – 1 Nutraceuticals Unit – 2 Cosmetics & ayurvedic Unit – 3 Pet supplements & homecare Capacity utilization: 93% Capacity utilization: 90% Capacity utilization: 66% 300 3,000 500 1,800 10,000 2,000 1,500 7,000 1,500 FY23 FY24 FY25 FY23 FY24 FY25 FY23 FY24
Slide 17: Massive increase in output post commissioning of our new capacity
Massive increase in output post commissioning of our new capacity Unit – 1 Nutraceuticals Unit – 2 Cosmetics & ayurvedic Expanded tablet capacity to 1,230 kg per day; Doubled liquid & sachet throughput to 48,000 bottles & 98,000 sachets per shift. 16
Slide 18: Industry leading certification and compliance systems
Industry leading certification and compliance systems Industry leading certifications and accreditations enhancing our ability to further revenue growth Adherence to high quality standards Prevents unsafe food from reaching consumers Reduces risks like contamination, errors, or unsafe products Build
Slide 19: Awards and recognition
Awards and recognition 2015 2016 2016 2018 2025 Best Nutraceutical Company of Best Sports Supplement Best Sports Supplement Innovative Nutraceuticals Grade A+ Exemplar the Year 2015 in 3rd Party Manufacturing Company of the Manufacturing Company of the of the Year, 2018. Certification, 2025. Certifi
Slide 20: Passionate and purpose-driven team
Passionate and purpose-driven team Dr. M.A. Chandniwala Mrs. Shirin Chandniwala Dr. A.A. Chandniwala Dr. Vipul Patel Mr. Ashok Kumar Jain (MD & Chairman) Whole-time Director Director Independent Director Independent Director Industry experience: 22+ years Industry experience: 12+ years Industry expe
Slide 21: Agenda
Agenda 1. Executive summary 2. About Influx Healthtech Limited 3. Competitive moats 4. 4.Investment Investmentrationale rationale 5. Historical business performance 6. Select financial statement data 7. Annexures
Slide 22: Investment rationale: Influx Healthtech Limited
Investment rationale: Influx Healthtech Limited Diversified Product Portfolio Wide-Ranging Client Base Advanced Formulation Development Multi-nutritional tablets, dietary A strong presence across cosmetics, supplements, ayurvedic products, oral Specializes in formulation pharmaceuticals, and homecar
Slide 23: Agenda
Agenda 1. Executive summary 2. About Influx Healthtech Limited 3. Competitive moats 4. Investment rationale 5. 2. Historical 5. About business Influx Historical performance Healthtech business Limited performance 6. Select financial statement data 7. Annexures
Slide 24: Historic business performance (1/3)
Historic business performance (1/3) Revenue Revenue from from operations operations (₹ (₹ crs.) crs.) RevenueEBITDA from operations (₹ crs.) (₹ crs.) Revenue from PAToperations (₹ crs.) (₹ crs.) 100 105 21 13 76 17 11 11 7 FY23 FY24 FY25 FY23 FY24 FY25 FY23 FY24 FY25 Revenue from Gross operations Pr
Slide 25: Historic business performance (2/3)
Historic business performance (2/3) Revenue fromROE operations 1 (₹ crs.) Revenue from operations Debtor Days (₹ crs.) RevenueInventory from operations Days (₹ crs.) 62% 113 112 49% 37% 66 58 41 18 FY23 FY24 FY25 FY23 FY24 FY25 FY23 FY24 FY25 RevenueAsset from operations Turnover (₹ crs.) Revenue Ca
Slide 26: Historic business performance (3/3)
Historic business performance (3/3) Revenue fromconcentration Revenue operations (₹1 crs.) Revenue fromconcentration Supplier operations (₹1 crs.) Revenue fromfrom Cash flow operations (₹ crs.) operations 49% 39% 9 39% 48% 7 7 46% 36% FY23 FY24 FY25 FY23 FY24 FY25 FY23 FY24 FY25 Revenue from operati
Slide 27: Agenda
Agenda 1. Executive summary 2. About Influx Healthtech Limited 3. Competitive moats 4. Investment rationale 5. Historical business performance 2. 6.About Select Influx Healthtech financial Limited statement data 7. Annexures
Slide 28: Income Statement
Income Statement ₹ crores unless otherwise mentioned Particulars FY24 FY25 YoY change (%) Revenue from operations 99.9 104.9 5% Cost of materials consumed including finished goods and WIP 64.9 63.4 -2% Employee benefits expense 7.0 8.8 25% Total operating expenses (incl. other expenses) 83.0 84.3 1%
Slide 29: Balance Sheet
Balance Sheet ₹ crores unless otherwise mentioned Assets FY24 FY25 YoY change (%) PPE and intangible assets 13.7 18.8 37% Non-current assets 1.7 2.5 49% Cash and investments 3.6 1.9 -47% Trade Receivables 15.9 32.4 104% Inventories 5.5 13.2 142% Other current assets 0.7 1.5 107% Total 41 70 71% Equi
Slide 30: Cash Flow
Cash Flow ₹ crores unless otherwise mentioned Cash flow from Operating Activities FY24 FY25 YoY change (%) Net Profit before tax & extraordinary items 14.9 17.9 20% Depreciation & amortization expenses 1.9 2.8 52% Other adjustment 0.4 0.0 -103% Trade Receivables -2.3 -16.6 615% Trade payables 0.5 15
Slide 31: Annexures: Industry Outlook
Agenda 1. Executive summary 2. About Influx Healthtech Limited 3. Competitive moats 4. Investment rationale 5. Historical business performance 6. Select financial statement data 7. 7. Annexures Annexures: Industry Outlook
Slide 32: India's CDMO industry to grow 2x global industry
India’s CDMO industry to grow 2x global industry Global CDMO industry (In $ bn) Levers driving growth of India’s CDMO industry 278 7.2% CAGR Strategic shift toward outsourcing ▪ Pharma firms outsource to CDMOs for cost savings and expertise, with CDMOs offering end-to-end drug development services C
Slide 33: India's nutraceutical industry: $76 bn opportunity
India’s nutraceutical industry: $76 bn opportunity Global nutraceutical industry (In $ bn) Growth drivers of India’s nutraceutical industry 919 7.6% CAGR Lifestyle shifts with rising health consciousness ▪ Rising health awareness and lifestyle changes are driving demand for nutraceuticals 591 Suppor
Slide 34: Thank you
Thank you For any further information/factory visit request, please contact: Company Investor relations consultant Influx Healthtech Ltd. Capital Bridge Advisory Service Private Ltd Mr. Ashish Shah, CFO Mr. Rutul Shah Mr. Raj Shah, CFA cs@influxhealthtech.com rutul@capbridge.com raj@capbridge.com +9